What is ANI Pharmaceuticals's revenue?

ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.

Is ANI Pharmaceuticals profitable?

ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.

What are ANI Pharmaceuticals's profit margins?

Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.

What is ANI Pharmaceuticals's earnings per share?

ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.

Where does ANI Pharmaceuticals's income statement data come from?

Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ANI Pharmaceuticals ANIP Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$237.46M+20.5%	$247.06M+29.6%	$227.81M+53.6%	$211.37M+53.1%	$197.12M+43.4%
Total cost of revenue	$93.58M+28.1%	$100.27M+24.9%	$93.39M+48.1%	$74.62M+29.3%	$73.04M+48.6%
Gross profit	$143.88M+16.0%	$146.79M+33.1%	$134.42M+57.7%	$136.76M+70.2%	$124.09M+40.6%
Gross margin	60.6%-2.4pp	59.4%+1.5pp	59%+1.5pp	64.7%+6.5pp	62.9%-1.3pp
Research and development	$10.6M+0.3%	$12.26M-26.3%	$12.3M+21.5%	$16.54M+127%	$10.56M+0.5%
Selling, general and administrative	$73.66M-3.8%	$82.79M+18.7%	$76.66M-3.1%	$81.77M+54.8%	$76.53M+59.4%
Total costs & expenses	$198.57M+16.2%	$212.29M+8.9%	$191.57M+13.5%	$197.48M+48.6%	$170.93M+45.9%
Operating income	$38.89M+48.5%	$34.77M—	$36.24M+277%	$13.89M+169%	$26.19M+29.0%
Operating margin	16.4%+3.1pp	14.1%—	15.9%+29.7pp	6.6%+2.8pp	13.3%-1.5pp
Interest expense	-$3.77M+31.3%	-$4.41M+26.7%	-$4.73M-103%	-$5.44M-16.8%	-$5.48M-19.2%
Other income (expense), net	-$651K-429%	$850K+162%	-$853K+66.4%	$1.74M+2,076%	$198K+719%
Income before income taxes	$40.22M+101%	$31.48M+329%	$33.8M+207%	$10.53M+560%	$19.99M-21.1%
Income tax expense	$10.73M+149%	$3.99M+214%	$7.18M+198%	$1.98M—	$4.31M-39.6%
Net income	$29.49M+88.1%	$27.49M+368%	$26.62M+210%	$8.55M+474%	$15.68M-13.9%
Net margin	12.4%+4.5pp	11.1%+16.5pp	11.7%+28.0pp	4%+5.7pp	8%-5.3pp
Diluted earnings per share	$1.28+85.5%	$1.17+313%	$1.13+189%	$0.36+357%	$0.69-15.9%
EBITDA	$59.81M+21.8%	$57.38M+1,933%	$58.87M+1,334%	$37.17M+87.1%	$49.09M+40.3%
EBITDA margin	25.2%+0.3pp	23.2%+21.7pp	25.8%+29.1pp	17.6%+3.2pp	24.9%-0.6pp
EBIT	$38.89M+48.5%	$34.77M+276%	$36.24M+277%	$13.89M+169%	$26.19M+29.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about ANI Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's revenue?: ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.
Is ANI Pharmaceuticals profitable?: ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.
What are ANI Pharmaceuticals's profit margins?: Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
What is ANI Pharmaceuticals's earnings per share?: ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.
Where does ANI Pharmaceuticals's income statement data come from?: Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.